Endocan - A novel inflammatory indicator in newly diagnosed patients with hypertension: A pilot study

Angiology

Volumn 65, Issue 9, 2014, Pages 773-777

  Balta, Sevket ^a   Mikhailidis, Dimitri P ^b   Demirkol, Sait ^c   Ozturk, Cengiz ^c   Kurtoglu, Ertugrul ^d   Demir, Mustafa ^c   Celik, Turgay ^c   Turker, Turker ^c   Iyisoy, Atila ^c  

^a ESKISEHIR MILITARY HOSPITAL   (Turkey)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d MALATYA STATE HOSPITAL   (Turkey)

Author keywords

endocan; inflammation; newly diagnosed hypertension

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOCAN; ESM1 PROTEIN, HUMAN; PROTEOGLYCAN; TUMOR PROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; HYPERTENSION; IMMUNOLOGY; INFLAMMATION; MALE; MIDDLE AGED; NEWLY DIAGNOSED HYPERTENSION; PILOT STUDY; PREDICTIVE VALUE; PROGNOSIS; UPREGULATION;

ENDOCAN; INFLAMMATION; NEWLY DIAGNOSED HYPERTENSION;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEOGLYCANS; UP-REGULATION;

EID: 84905673004     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319713513492     Document Type: Article

References (24)

1. Karaman M, Balta S, Ay SA, et al. The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. Clin Exp Hypertens. 2013;35(7):516-522.
2. Altun B, Bulucu F, Demirbas S, et al. The relationship between some of the cardiovascular risk factors and arterial stiffness parameters in essentially hypertensive patients. Clin Exp Hypertens. 2013;35(6):444-448.
3. Unlu M, Karaman M, Ay SA, et al. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. Clin Exp Hypertens. 2013;35(6):418-423.
4. Lassalle P, Molet S, Janin A, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458-20464.
5. Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25-37.
6. Balta S, Demirkol S, Celik T, et al. Association between coronary artery ectasia and neutrophil-lymphocyte ratio. Angiology. 2013;64(8):627-632.
7. Demirkol S, Balta S, Celik T, et al. Carotid intima media thickness and its association with total bilirubin levels in patients with coronary artery ectasia [published online January 27, 2013]. Angiology. 2013. doi: 10.1177/0003319712473796
8. Libby P. Inflammation and Atherosclerosis. Circulation. 2002;105(9):1135-1143.
9. Scherpereel A, Depontieu F, Grigoriu B, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34(2):532-537.
10. Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behc¸et's disease [published online October 28, 2013]. J Am Acad Dermatol. 2013.
11. Balta I, Balta S, Demirkol S, et al. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066-1070.
12. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281-1357.
13. Chobanian A V, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572.
14. Kabakci G, Aydin M, Demir I, Kirma C, Özerkan F. Global cardiometabolic risk profile in patients with hypertension: results from the Turkish arm of the pan-European GOOD survey. Turk Kardiyol Dern Ars. 2010;38(5):313-320.
15. Bechard D, Meignin V, Scherpereel A, et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res. 2000;37(5):417-425.
16. Morillas P, de Andrade H, Castillo J, et al. Inflammation and apoptosis in hypertension. Relevance of the extent of target organ damage. Rev Esp Cardiol (Engl Ed). 2012;65(9):819-825.
17. Sengoren O, Anar C, Usta L, Ozacar R, Halilcolar H, Bicmen C. Relationship between functional and non-functional parameters, and quality of life and CRP in patients with chronic obstructive pulmonary disease. Gulhane Med J. 2012;54(2):93-103.
18. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003;17(4):223-230.
19. Davey Smith G, Lawlor DA, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol. 2005;25(5):1051-1056.
20. Béchard D, Scherpereel A, Hammad H, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099-3106.
21. Béchard D, Gentina T, Delehedde M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276(51):48341-48349.
22. Zhang SM, Zuo L, Zhou Q, et al. Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87(3):172-178.
23. Delehedde M, Devenyns L, Maurage C-A, Vivès RR. Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol. 2013;2013:705027.
24. Shin JW, Huggenberger R, Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood. 2008;112(6):2318-2326.